SCHEMBL7575441

SCHEMBL7575441

CN(C(=O)CCNC(=O)N1CCC(Nc2ccc(CCNC(=O)OC(C)(C)C)cc2)CC1)c1ccc(Cl)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.45
ADRB3 P13945 6/20 0.44
ALDH1A1 P00352 2/20 0.42
NPC1 O15118 1/20 0.42
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SIGMAR1 Q99720 2/20 0.42
ADRB1 P08588 4/20 0.41
DRD2 P14416 3/20 0.40
CNR1 P21554 1/20 0.39
TPSAB1 Q15661 1/20 0.38
TPSD1 Q9BZJ3 1/20 0.38
TPSG1 Q9NRR2 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7575436 0.88 NAMPT (0.47) NAMPTADRB3ALDH1A1NPC1MAPT
SCHEMBL7091374 0.86 NAMPT (0.48) NAMPTADRB3ALDH1A1NPC1MAPT
SCHEMBL7575447 0.85 ALDH1A1 (0.43) NAMPTADRB3ALDH1A1NPC1MAPT
Formic Acid SCHEMBL7090690 0.83 ADRB3 (0.46) ADRB3ADRB1CNR1TPSAB1TPSD1
SCHEMBL7091903 0.81 NAMPT (0.48) NAMPTADRB3ALDH1A1NPC1MAPT
SCHEMBL7091709 0.80 ADRB3 (0.59) NAMPTADRB3ALDH1A1NPC1MAPT
SCHEMBL7095299 0.79 NAMPT (0.51) NAMPTADRB3ALDH1A1NPC1MAPT
Formic Acid SCHEMBL7091936 0.77 TPSAB1 (0.48) NAMPTADRB3ALDH1A1NPC1MAPT
SCHEMBL7095896 0.75 TAAR1 (0.53) NAMPTALDH1A1NPC1MAPTMAPK1
SCHEMBL7091441 0.75 ADRB3 (0.55) ADRB3ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6451814-B1 SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION WYETH 2002-09-17 US disclosed
US-20020028832-A1 Heterocyclic beta-3 adrenergic receptor agonists AMERICAN HOME PRODUCTS CORPORATION (US) 2002-03-07 US disclosed
WO-2002006229-A2 HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS WYETH (US) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028832-A1 Heterocyclic beta-3 adrenergic receptor agonists ADRB1, ADRB3, ADRB2 NAMPT 2909/4885ADRB3 2/4885ALDH1A1 524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.